JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) marked an important juncture in. BNP in 11, participants without cardiovascular disease in the JUPITER Un Estudio Intervencionista que Evalúa Rosuvastatina (JUPITER, Justification. Desde que en el estudio JUPITER 34 se detectó una mayor incidencia de DM en el grupo con rosuvastatina 35, varios metaanálisis han.
| Author: | Duramar Gardacage |
| Country: | Swaziland |
| Language: | English (Spanish) |
| Genre: | Education |
| Published (Last): | 27 December 2018 |
| Pages: | 401 |
| PDF File Size: | 3.37 Mb |
| ePub File Size: | 17.81 Mb |
| ISBN: | 629-6-96335-548-8 |
| Downloads: | 53164 |
| Price: | Free* [*Free Regsitration Required] |
| Uploader: | Malajora |
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome.
ApoA-1 ratio as an important predictor of myocardial infarction. In this patient group, choice is often limited and determined by the anti-retroviral regimen. Open in a separate window. All statins can cause myopathy and rhabdomyolysis especially at higher doses. Data from Hippisley-Cox et al. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: The superior lipid lowering effect of rosuvastatin makes it a good candidate for intensive lipid lowering.
The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Consistent effects were observed in all subgroups evaluated. The mean volume of distribution is litres in steady state. Articles from Clinical Medicine Insights.
A recent large prospective cohort study of primary care patients from general practices in England and Wales reported findings frompatients who commenced statin therapy between and A large retrospective cohort study in America found that rosuvastatin produced the largest reduction in LDL-C, non-HDL-C and triglycerides when compared with atorvastatin and pravastatin.
A new category of patients is thus created by those who fail to achieve these goals with various treatments. Protease inhibitors such as ritonavir, saquinavir and atazanavir inhibit OATP-1B1 the transporter protein involved in the hepatic cell uptake of rosuvastatin. Clinical studies have demonstrated the benefits of statins in primary prevention. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
This is an open access article.
Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
It must be noted that the study was non-comparative and open label. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Clearfield MB, Amerena J, et al. This leads to higher serum rosuvastatin concentrations in patients taking protease inhibitors. Patients on HAART should be considered for treatment with rosuvastatin whenever their treatment allows.
Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease
Rosuvastatin in primary prevention Clinical studies have demonstrated the benefits of statins in primary prevention. The beneficial effects of statin therapy in patients with ischaemic heart disease are well known. ApoA-1 ratio compared to other statins.
In conclusion jupitdr is an effective and safe statin which is ideal second line treatment for most patients requiring primary or secondary prevention. We conducted a Medline literature search to identify rosuvastatin papers published in English.
Special groups Patients with hereditary hyperlipidaemia, particularly FH and FCH should be considered for early treatment with rosuvastatin. These benefits were present in all patient groups including women, non smokers and other low risk patients.
This enzyme converts HMG-CoA to mevalonic acid in the cholesterol biosynthetic pathway which is the rate limiting step in cholesterol synthesis. Am J Rosuvastatkna Dis. Advanced kidney disease is associated with high cardiovascular morbidity and death.
Epidemiological studies have established a strong correlation between cholesterol and jupitre incidence of cardiovascular disease. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. Because of its potency, rosuvastatin can be used at very low doses. Several studies have suggested that reduction in plaque volume is linked to the clinical outcome.
Eur J Cardiovasc Prev Rehabil. They are also at very high cardiovascular risk. The use of rosuvastatin did however reduce hospitalisation from cardiovascular causes.
Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: